Janus Henderson Group
HRTX icon

Janus Henderson Group’s Heron Therapeutics HRTX Stock Holding History

Janus Henderson Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-44,526
Closed -$67.5K – 2636
2023
Q1 		$67.5K Buy
44,526
+26,787
+151% +$67.1K ﹤0.01% 2644
2022
Q4 		$44.3K Buy
17,739
+2
+0% +$6 ﹤0.01% 2423
2022
Q3 		$75K Buy
17,737
+46
+0.3% +$180 ﹤0.01% 2089
2022
Q2 		$50K Sell
17,691
-39
-0.2% -$157 ﹤0.01% 2554
2022
Q1 		$102K Buy
+17,730
New +$130K ﹤0.01% 2556
2020
Q4 		– Sell
-464,301
Closed -$6.88M – 1403
2020
Q3 		$6.88M Sell
464,301
-216,454
-32% -$3.38M ﹤0.01% 879
2020
Q2 		$10M Sell
680,755
-2,489,265
-79% -$40.9M 0.01% 805
2020
Q1 		$37.2M Sell
3,170,020
-1,745,293
-36% -$32.8M 0.03% 526
2019
Q4 		$116M Sell
4,915,313
-214,028
-4% -$4.74M 0.06% 326
2019
Q3 		$94.9M Buy
5,129,341
+19,617
+0.4% +$361K 0.05% 385
2019
Q2 		$95M Sell
5,109,724
-87,951
-2% -$1.76M 0.05% 389
2019
Q1 		$127M Sell
5,197,675
-239,865
-4% -$6.28M 0.07% 319
2018
Q4 		$141M Buy
5,437,540
+10,549
+0.2% +$290K 0.09% 272
2018
Q3 		$172M Sell
5,426,991
-443,819
-8% -$16.5M 0.09% 261
2018
Q2 		$228M Sell
5,870,810
-2,150,540
-27% -$68.5M 0.13% 203
2018
Q1 		$221M Buy
8,021,350
+959,488
+14% +$21.8M 0.13% 198
2017
Q4 		$128M Buy
7,061,862
+1,294,367
+22% +$21.1M 0.08% 308
2017
Q3 		$93.1M Buy
5,767,495
+126,039
+2% +$1.98M 0.06% 380
2017
Q2 		$78.1M Buy
+5,641,456
New +$81.7M 0.05% 408

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $2.3B AUM 29.92% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return

Janus Henderson Group's HRTX Position: Q2 2023 in Review

Janus Henderson Group sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 44,526 shares — an estimated $67.5K sold.

Janus Henderson Group first reported a position in HRTX in Q2 2017 and held it in 19 quarters. The position peaked at $228M in Q2 2018. 148 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • Janus Henderson Group reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Janus Henderson Group sold 44,526 Heron Therapeutics shares in Q2 2023, an estimated $67.5K.
  • Janus Henderson Group first reported a position in Heron Therapeutics in Q2 2017 and held it in 19 quarters.
  • Janus Henderson Group's Heron Therapeutics position peaked at $228M in Q2 2018.
  • 148 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Janus Henderson Group's 13F filing for Q2 2023, filed 14 Aug 2023.